Immune checkpoint inhibitor induced large vessel vasculitis

This is a case report of a 67-year-old patient with castration resistant metastatic prostate cancer who developed an immune-mediated large vessel vasculitis following treatment with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMJ Case Rep
Main Authors: Henderson, Daisy, Eslamian, Gelareh, Poon, Daniel, Crabb, Simon, Jones, Robert, Sankey, Peter, Kularatne, Bihani, Linch, Mark, Josephs, Debra
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2020
Teme:
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7239530/
https://ncbi.nlm.nih.gov/pubmed/32430351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-233496
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki